The Journal of Urology
Volume 163, Issue 5 , Pages 1451-1456 , May 2000

EFFECTS OF A SAW PALMETTO HERBAL BLEND IN MEN WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA

,Accepted 12 November 1999.

REFERENCES 

  1. Marks LS , Tyler VE . Saw palmetto extract: newest (and oldest) treatment alternative for men with symptomatic benign prostatic hyperplasia . Urology . 1999;53:457
  2. Wilt TJ , Ishani A , Stark G , et al.   Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review . JAMA . 1998;280:1604
  3. Buck AC . Phytotherapy for the prostate . Brit J Urol . 1996;78:325
  4. Lowe FC , Ku JC . Phytotherapy in treatment of benign prostatic hyperplasia: a critical review . Urology . 1996;48:12
  5. Lowe FC , Fagelman E . Phytotherapy in the treatment of benign prostatic hyperplasia: an update . Urology . 1999;53:671
  6. Marks LS , Partin AW , Gormley GJ , et al.   Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia . J Urol . 1997;157:2171
  7. Marks LS , Partin AW , Dorey FJ , et al.   Long-term effects of finasteride on prostate tissue composition . Urology . 1999;53:574
  8. Hodge KK , McNeal JE , Terris MK , et al.   Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate . J Urol . 1989;142:71
  9. Kyprianou N , Litvak JP , Borkowski A , et al.   Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia . J Urol . 1998;159:1810
  10. Bostwick DG , Wheeler TM , Blute M , et al.   Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies . Urology . 1996;48:47
  11. Perry KT , Anthony CT , Steiner MS . Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in normal and malignant human prostate . Prostate . 1997;33:133
  12. Prins GS , Sklarew RJ , Pertschuk LP . Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy . J Urol . 1998;159:641
  13. Carraro J-C , Raynaud J-P , Koch G , et al.   Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1098 patients . Prostate . 1996;29:231
  14. Eisenberg DM , Davis RB , Ettner SL , et al.   Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey . JAMA . 1998;280:1569
  15. Rhodes L , Primka RL , Berman C , et al.   Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition . Prostate . 1993;22:43
  16. Strauch G , Perles P , Vergult G , et al.   Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers . Eur Urol . 1994;26:247
  17. Weisser H , Behnke B , Helpap B , et al.   Enzyme activities in tissue of human benign prostatic hyperplasia after three months’ treatment with the Sabal serrulata extract IDS 89 (Strogen) or placebo . Eur Urol . 1997;31:97
  18. Helpap B , Oehler U , Weisser H , et al.   Morphology of benign prostatic hyperplasia after treatment with Sabal extract IDS 89 or placebo . J Urol Pathol . 1995;3:175
  19. Gerber GS , Bales G , Kirsh E , et al.   Medicinal botanicals in the treatment of lower urinary tract symptoms (LUTS): a demographic analysis of awareness and use at the University of Chicago . J Urol . 1998;159(suppl.):334; abstract 1282
  20. Nam RK , Fleshner N , Rakovitch E , et al.   Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis . J Urol . 1999;161:1521
  21. Angell M , Kassirer JP . Alternative medicine—the risks of untested and unregulated remedies . N Engl J Med . 1998;339:839
  22. Dietary Supplement Health and Education Act of 1994. Public Law 103–417.
  23. Slifman NR , Obermeyer WR , Aloi BK , et al.   Contamination of botanical dietary supplements by Digitalis lanata . N Engl J Med . 1998;339:806

 Editor’s Note:This article is the second of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 1540 and 1541.

PII: S0022-5347(05)67641-0

The Journal of Urology
Volume 163, Issue 5 , Pages 1451-1456 , May 2000

Article Tools

* Image Usage & Resolution